Authors
Xin Hui S Chan, Anna P Durbin, Gathsaurie Neelika Malavige, Fausto Baldanti, Marco Cavaleri, Fazle Rabbi Chowdhury, Isadora C de Siqueira, Madiha Hashmi, Trung Trieu Huynh, Jenny G Low, Tariq A Madani, Johan Neyts, Usa Thisyakorn, Sandra L Valderrama-Beltrán, Janet V Diaz, Vasee Moorthy, Martina Penazzato, Diana P Rojas, Raman Velayudhan
Published in
The Lancet. Microbe. Pages 101451. May 19, 2027. Epub May 19, 2027.
Abstract
Dengue, an Aedes mosquito-borne viral infection, is on the rise with climate and demographic change. In 2023, WHO declared dengue its highest grade of emergency, following the largest number of cases and deaths in recorded history. This emergency highlighted the absence of safe and effective dengue-specific treatments as a gap in the product landscape for care for people with dengue. To accelerate development of dengue-specific treatments for wide implementation and access in all dengue-endemic countries, WHO conducted a landscape analysis of the dengue therapeutics pipeline and convened a global expert and public consultation to develop target product profiles for treatments for non-severe and severe dengue. These target product profiles provide strategic guidance for product developers, regulators, procurement agencies, and funders on the intended use, target populations, and key product characteristics of dengue-specific treatments required to meet public health needs, setting clear targets to drive development of dengue drugs accessible to those who need them the most.
PMID:
42685738
Bibliographic data and abstract were imported from PubMed on 03 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0